Tuesday's drug price decontrol decision has apparently been more of a political move than a policy announcement. While the pharmaceutical policy has been in the pipeline for almost two years, sources say the Cabinet approved it despite objections raised by the finance ministry.
A more complete policy announcement is expected on Monday, while the specific fiscal incentives to be given to Indian pharmaceutical companies for research and development will be announced in the Budget. The finance ministry was in favour of announcing the entire roadmap at one-go.
The announcement said there would be incentives without spelling out the details as it would have put pressure on the ministry from different sources with the Budget just round the corner. The Cabinet yesterday approved the criteria on the basis of which drugs would be brought under price control, a decision which will sharply reduce the number of bulk drugs under price control and the span of price control in the formulations market.
Most Indian pharma companies are expected to benefit from the policy announcement.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
